Stay updated on Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page.

Latest updates to the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page
- Check7 days agoChange Detected- Revision: v3.4.3 added; previous v3.4.2 removed. This update affects only the page's version label and does not alter study content or functionality.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedAdministrative updates: Revision: v3.4.2 is added and older notices (v3.4.1) are removed; these changes do not affect the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check43 days agoChange DetectedAdded a site-wide funding status notice directing users to cc.nih.gov and opm.gov, and updated the page version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check50 days agoChange DetectedAdded UI elements: a Show glossary toggle and a new 'Last Update Submitted that Met QC Criteria' label. Updated footer text to display 'No FEAR Act Data' and 'Revision: v3.4.0'.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision history updated: added v3.3.4 and removed v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded a comprehensive Locations section listing numerous sites across the US and internationally and removed older per-state location groupings. The update updates where the study is conducted and how sites are presented on the page.SummaryDifference1%

Stay in the know with updates to Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page.